Alemtuzumab is a very effective treatment of multiple sclerosis, with significant – and potentially serious – side-effects.
The important and common side-effects are autoimmune diseases affecting the thyroid gland (30% risk), the platelets of the blood (3% risk) and the kidneys (0.1% risk). People receiving alemtuzumab should make sure they are part of a safety monitoring programe (which includes monthly blood tests) for at least four years after the last dose of treatment.
There are more detaiuls in the patient information available here.
Advice for prescribers
We recommend that prescribers should familiarise themselves with the summary of product charateristics here